This year, Neurosom arrived at LSI with strong momentum, including: an oversubscribed bridge funding round as the company advances toward a seed round in the first half of 2026; patent allowance for Sleep WISP® to measure brain impedance in relation to extracellular space and to index metabolic waste clearance; a new publication accepted in SLEEP Journal titled “tES Synchronization of Slow Oscillations in N3 Sleep Decreases Brain Electrical Impedance: Implications for Improved Brain Waste Clearance”; recognition as the winner of the 2025 Oregon Entrepreneurs Network Angel Oregon Life & BioScience Award; and the launch of a second Parkinson’s disease study at Mount Sinai using the Sleep WISP.

SLEEP, the Journal of the Sleep Research Society, accepted for publication on March 13, 2026, 'tES Synchronization of Slow Oscillations in N3 Sleep Decreases Brain Electrical Impedance: Implications for Improved Brain Waste Clearance', by Schofner et al. (2026)The publication abstract states, "Sleep appears to be a critical period for the brain’s removal of metabolic waste products through its lymph system, which involves both perivascular cerebrospinal fluid (CSF) flow, transport of CSF through the extracellular space of the parenchyma, and glial (aquaporin 4 end feet) transfer across the blood-brain barrier. The decline of waste removal with the decline of stage N3 sleep in aging may be relevant to the neurodegeneration leading to dementia. The present results suggest that tES strategically applied at key sleep stages, such as the N2-N3 transition, may not only enhance the duration of N3 and REM sleep, but may facilitate the transient ECS expansion driven by cardiac pulses and respiration that supports brain waste clearance in healthy sleep."The research analyzed in this publication was conducted using the Neurosom Sleep WISP®, a wearable EEG/tES sleep-therapy headband designed to increase time spent in deep sleep and improve cognitive health. The authors of this publication include Steven Shofner, Kyle Morgan, Phan Luu, Roma Shusterman, Alexei Doncov, Jeff Heys, Lori Ray, Dr. Miranda Lim, M.D., Ph.D. (OHSU), and Don Tucker.

Neurosom® is pleased to announce that a generous donor has funded a new Parkinson’s disease study at the Icahn School of Medicine at Mount Sinai to continue research using the Sleep WISP® therapy system. The study will be supported by the Glickenhaus Research Scholar Award and will be led by Dr. Allison C. Waters, PhD, Director of the Waters Lab within the Nash Family Center for Advanced Circuit Therapeutics and Medical Advisor to Neurosom, in collaboration with a multidisciplinary clinical team including Dr. Joohi Jimenez-Shahed, Dr. Emmanuel During, MD, and Dr. Rachel Fremont.

- Neurosom's mission is to improve aging, brain health, and reduce the risk of dementia through noninvasive sleep therapy.
- The Sleep WISP headband uses AI to track EEG stages and apply personalized gentle stimulation to optimize deep sleep, comfortably used at home.
- The company won the Investment from the Angel Oregon Life and BioScience Award Program in December, recognizing its innovation and clinical potential.
- Neurosom led a successful oversubscribed bridge round shortly after the AOBIO award win.
- The company received FDA clearance in 2025 for NEAT AI-powered software, which accurately assesses the sleep stages and programs personalized therapy.
- The Sleep WISP has also received a patent allowance for measuring Glymphatic Clearance Capacity through skin-brain impedance measures, adding the ability to not only register the change in glymphatic waste clearance in the brain, but also to improve glymphatic flow through the stimulation of the Sleep WISP.

Dr. Don Tucker, PhD, Chief Scientific Officer, and Dr. Phan Luu, Chief Technology Officer, of Neurosom® will attend the Oxford Glymphatic & Brain Clearance Symposium. Held at Oxford's prestigious Keble College, will bring together leading experts on metabolic waste clearance, including keynote speaker Dr. Maiken Nedergaard, D.MSc., considered to be the discoverer of the "glymphatic system." Program topics will include sleep-related physiology, pathways for CSF clearance, and valid measures of glymphatic function.

Building on the strengths of Sleep WISP and NEAT technology, we can now enhance the ECS (extracellular space) in the brain to clear metabolic waste through a unique AI-driven brain-impedance computation. This breakthrough provides an objective metric of glymphatic function—adding another valuable capability to Sleep WISP.

Over the past few weeks, we’ve explored the discovery of this system and how the Sleep WISP is designed to support its natural clearance process by extending time spent in N3 deep sleep—the stage most closely associated with restorative brain function.
We’ve also shared how our FDA-cleared NEAT software uses advanced AI to analyze EEG signals, optimize sleep architecture, and support long-term brain health, including strategies to reduce the risk of dementia.
Better sleep. Smarter technology. Healthier brains.

NEAT, our FDA-cleared sleep staging software, was built using a deep neural network trained on multi-site PSG datasets. With high accuracy, NEAT detects when a sleeper has remained in Stage 2 sleep for the appropriate duration and guides Sleep WISP stimulation to help transition the sleeper—in most cases—into deep sleep.

The paper outlined how the brain uses a specific anatomical structure and cerebrospinal fluid (CSF) to clear itself of harmful metabolic waste. For years, scientists had speculated that CSF flow in the brain had a waste-clearing mechanism, but were unable to prove it due to a lack of imaging technology. Nedergaard and her lab were able to study the brain structure in healthy mice using "two-photon microscopy", which allows scientists to see the flow of blood, CSF, and other fluids in a living brain. Nedergaard named the structure the "glymphatic system" for its similarity to the lymphatic system and for the role of "glial" brain cells in the process.

This February, we’ll focus on the brain’s glymphatic system: a fluid-based pathway that clears metabolic waste from the brain. This process is critical, as waste buildup has been linked to neurodegenerative diseases like Alzheimer’s and Parkinson’s.
𝗛𝗼𝘄 𝗰𝗮𝗻 𝗡𝗲𝘂𝗿𝗼𝘀𝗼𝗺 𝗵𝗲𝗹𝗽?
The 𝗦𝗹𝗲𝗲𝗽 𝗪𝗜𝗦𝗣 has been shown to extend deep sleep (N3)—the sleep stage most closely associated with metabolic waste clearance. By optimizing deep sleep, the 𝗦𝗹𝗲𝗲𝗽 𝗪𝗜𝗦𝗣 supports the brain’s natural waste-removal process and overall brain health.

LSI USA '26 will take place March 16-20 in Dana Point, CA. Reach out through the app or onsite to connect and learn more about how Neurosom is changing the future of brain care and dementia prevention.

Neurosom scientist and collaborators at Mount Sinai published a paper, "Emerging Neurotechnological Approaches to Management of Sleep Disturbances in Parkinson's Disease," in Clinical Parkinsonism and Related Disorders. Lead author, Mason Dallegge, a scientist at the Ichan School of Medicine, Mount Sinai Department of Neuroscience, and Dr. Allison C. Waters, PhD, Assistant Professor of Psychiatry and Neuroscience at the Nash Family Center for Advanced Circuit Therapeutics at the Ichan School of Medicine at Mount Sinai, led a team of medical professionals and scientists from Mount Sinai, along with Dr. Don Tucker, founder and Senior Scientist of Neurosom, to write an innovative paper on newfound ways to manage sleep disturbances in Parkinson's Disease (PD) through neurotechnology and neuromodulation.

The round was led by Portland Seed Fund’s Intrepid Oregon Fund, with participation from the Loomis Family Trust, OEN Angel Syndicate, and ONAMI, positioning the company to accelerate clinical progress and product development as it advances toward a priced Seed Round in the first half of 2026.

With recent FDA clearance of NEAT™, expanding clinical collaborations, and continued development of our Sleep WISP™ platform, 2026 is shaping up to be a pivotal year for Neurosom™.

Deep sleep, in particular, plays a critical role in physical recovery, brain health, and overall resilience. This well-written article breaks down how aging affects our sleep architecture, what each sleep stage means for the body’s recovery process, and practical ways to support more restorative nights.
Worth a read if you care about long-term health and performance.

Gamma-band synchronization, a form of brain activity, is important for everyday cognitive function and memory, yet we all tend to lose this functionality as we age. In this study by French scientists, some elderly individuals successfully trained their minds through neurofeedback, achieving Gamma-band synchronization. However, the level of success varies based on individual neural dynamics.

We started our journey with this program in April of this year, and we are so grateful for the mentorship, network, and guidance this fine community of Oregon Leaders has given us over the year. Cara Turano, Yalda Moshiri, Rylee O'Brien, and Sarah Norris, you've gone over and above for our company, and we can't wait to share our vision of better brain health with the rest of the world.

Neurosom is a finalist for the Oregon Entrepreneurs Network Angel Oregon Life and BioScience program, and the winner will be announced tonight and receive a $100,000 investment check! Our CEO, Viral Sheth, will attend and present our vision for better brain health, and regional investors will have the opportunity to invest in the local Oregon companies.

Researchers at Osaka Metropolitan University in Japan have published a new study where they found that the Alzheimer's drug Lecanemab removes amyloid plaques from the brain but does not restore the brain's ability to clear those plaques. The brain waste clearance system is the critical function that removes the toxic waste of the brain, which causes neurodegenerative diseases such as Alzheimer's.

Neurosom's CEO, Viral Sheth, accepted the Oregon Entrepreneurs Network Development Stage Award last Thursday night at the Hilton Hotel in Portland, Oregon. OEN has provided Neurosom™ with critical support and mentoring throughout 2025 as we advance our mission of personalized brain care, sleep therapy, and reduced dementia risk.

A new study published in Nature Neuroscience suggests that Alzheimer's disease disrupts the body's circadian rhythms, which in turn shut down genes that regulate proper brain function and the ability to clear the brain of waste and harmful materials, like amyloid plaques. Erik S. Musiek, MD, PhD, the Charlotte & Paul Hagemann Professor of Neurology at WashU Medicine, who led the study, finds hope in the new science.